Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post by Caris Life Sciences on LinkedIn:
“Clonal hematopoiesis as a predictive biomarker with IO therapy in solid tumors?
Fascinating research results from Shelley Herbrich and Milan Radovich that elucidates the putative underlying mechanism will be discussed in an upcoming webinar based on the recent Cancer Cell by Cell Press publication.
Our understanding of the clinical relevance of clonal hematopoiesis continues to touch on different biologic systems in human health ranging from hematologic malignancy to cardiovascular disease, and now an emerging impact on prognosis and immune system priming to respond to immunotherapy in solid tumors.”
Title: TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors
Authors: Shelley Herbrich, Mehdi Chaib, Swetha Anandhan, Samuel Andrewes, Ashwat Nagarajan, Baoxiang Guan, Nishant Gandhi, Jared Gilliam, Milan Radovich, Padmanee Sharma
Read the Full Article.
Other articles featuring Matthew Oberley on OncoDaily.